Lumosa and Center Lab to Hold Joint Investor Press Conference for Material Announcement on 24/11/29
1.Date of occurrence of the event:2024/11/29
2.Company name:Lumosa Therapeutics Co., Ltd.
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office
4.Reciprocal shareholding ratios:not applicable
5.Cause of occurrence:
Lumosa to hold joint investor and media conference on material
development with Center Laboratories Inc. at 16:00 PM, on
November 29, 2024, at 11th Floor of Taipei Exchange (11th Floor,
No. 100, Section 2, Roosevelt Road, Taipei).
6.Countermeasures:
Trading of the Company's shares has been suspended starting
November 29, 2024, as approved by TPEx.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
The Company will announce the unblinded data analysis results from the
Phase 2 clinical trial conducted in China for LT3001, a new therapy
for acute ischemic stroke.